5 Clinical trials Preclinical studies have identified a substantial number of oHSVs with diverse antitumor properties
(a) Gastrointestinal trials (Ulcerative Colitis) A Croatian research group conducted: A phase I safety study in healthy men A phase II trial of a rectal BPC-157 formulation for mildmoderate ulcerative colitis These are only available as abstracts and drug summaries , not as full peer-reviewed publications with methods, statistics, or adverse event profiles
pH Buffer (Optional): A small amount of citric acid or sodium hydroxide may be needed to balance pH to 4.55.5, the skin's natural range
Oral or troche dose: Determined at APRN intake based on your GI indication and treatment goal Troche format: Held sublingually for 60 to 90 seconds before swallowing for improved absorption Best use case: GI inflammation, IBS, gut lining repair, Crohns management, systemic anti-inflammatory support Not optimal for: Localized tendon, joint, or muscle injury where injection near the site is more targeted Injury vs Gut Protocol: See What Dosing Looks Like for Your Use Case BPC-157 dosage differs by indication
A 2026 biopharmaceutical review in a journal I do not trust said there is no identified high-affinity receptor, no validated molecular target, and a wide disconnect between the tidy preclinical effects and any coherent pharmacology
